PD-L1 significantly inhibits the proliferation and function of T cells through binding with programmed cell-death protein 1 (PD-1) on T cells; thus, its aberrant expression is closely associated with impaired tumor immunity and poor prognosis in patients [5]. This evidence concerns the gene PDCD1 and neoplasm.